Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S announced a capital increase of 28,011 shares resulting from employee warrant exercises, raising approximately DKK 44.3 million. The new shares represent 0.04% of the company's share capital and will be listed on Nasdaq Copenhagen. The total nominal share capital after the increase is DKK 62,405,855.

09/08/2026, 2:44 PM • GlobeNewswire

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

09/03/2026, 1:00 PM • GlobeNewswire

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Despite the trial failure, epcoritamab remains approved under accelerated approval and the companies continue to evaluate the therapy in other clinical programs.

07/23/2026, 4:00 PM • GlobeNewswire

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

The European Commission has approved TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. The Phase 3 EPCORE® FL-1 trial demonstrated that the fixed-duration combination therapy reduced disease progression or death risk by 79% compared to standard care, with 96% overall response rate and 74% complete response rate, offering a chemotherapy-free treatment option.

07/06/2026, 1:59 PM • GlobeNewswire

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable remissions and sustained MRD negativity.

06/13/2026, 12:45 PM • GlobeNewswire

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab A/S announced the disclosure of share transactions made by managerial employees and their closely associated persons in accordance with EU market abuse regulations. The company also announced a capital increase of 2,346 shares resulting from employee warrant exercises.

05/29/2026, 4:35 PM • GlobeNewswire

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms

The bispecific antibody drug conjugate (BsADC) market is expected to reach over $2 billion by 2030, with the first BsADC approval anticipated by 2028. Over 150 clinical trials are underway globally, with China leading development efforts. Key candidates like Izalontamab brengitecan and JSKN003 are showing positive clinical results in cancer treatment, positioning BsADCs as the next generation of targeted therapies.

04/21/2026, 4:49 AM • GlobeNewswire

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

The bispecific antibodies market is projected to reach over $60 billion by 2031, growing from $16 billion in 2025. With 18 approved bispecific antibodies and over 550 clinical trials underway, the market is transitioning toward commercial maturity driven by clinical progress in cancer, autoimmune, and inflammatory therapies. Major pharmaceutical players and emerging biotech companies are actively expanding their pipelines through strategic collaborations and technological innovation.

04/21/2026, 4:34 AM • GlobeNewswire

Genmab A/S Share Capital Reduction

Genmab A/S has completed a share capital reduction by canceling 1.9 million treasury shares, reducing total share capital from DKK 64.25 million to DKK 62.35 million. The reduction was approved at the Annual General Meeting on March 19, 2026, and registered with Danish authorities on April 17, 2026. Nasdaq systems will be updated by April 21, 2026.

04/17/2026, 10:56 AM • GlobeNewswire

Major Shareholder Announcement

Orbis Investment Management Limited has disclosed a 4.99% stake in Genmab A/S as of March 27, 2026, controlling 3,205,763 shares. The announcement was made under Danish Capital Markets Act requirements. Genmab also held its Annual General Meeting on March 19, 2026, where the 2025 Annual Report was approved and discharge was given to the Board of Directors and Executive Management.

03/30/2026, 12:00 PM • GlobeNewswire

Correction to Company Announcement No. 13 of March 2, 2026

Genmab A/S issued a correction to a previous company announcement regarding managerial employee share transactions, correcting the reported share price from DKK 0.00 to DKK 1,867.50. The announcement discloses vesting and net settlement of restricted stock units granted to executives Jan van de Winkel and Anthony Pagano in February 2023.

03/02/2026, 4:53 PM • GlobeNewswire

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S announced the vesting and net settlement of restricted stock units (RSUs) granted to executives Jan van de Winkel and Anthony Pagano on February 24, 2023, as part of deferred annual bonus achievement. The disclosure is made in accordance with EU market abuse regulations requiring transparency of insider trading activities.

03/02/2026, 2:58 PM • GlobeNewswire